Evidence map›Paper›PMID 38239865›Full record

ArticleContemporary oncology (Poznan, Poland)2023

Quercetin inhibits the activity and function of dendritic cells through the TLR4/IRAK4/NF-κB signalling pathway.

Chenglin Kang, Xiaomei Li, Peng Liu, Yue Liu, Yuan Niu, Xianhai Zeng, Jiangqi Liu, Hailiang Zhao, Shuqi Qiu

Open access · goldAbstract read
In one paragraph

Article in Contemporary oncology (Poznan, Poland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Potential of Orally Administered Quercetin, Hesperidin, andInternational journal of molecular sciences · 2025
    Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Chenglin Kang *Department of Graduate and Scientific Research, Zunyi Medical University Zhuhai Campus, Zhuhai, People's Republic of China.
Xiaomei Li *Department of Otolaryngology, Second People's Hospital of Gansu Province, Lanzhou, People's Republic of China.
Peng LiuDepartment of Graduate and Scientific Research, Zunyi Medical University Zhuhai Campus, Zhuhai, People's Republic of China.
Yue LiuDepartment of Graduate and Scientific Research, Zunyi Medical University Zhuhai Campus, Zhuhai, People's Republic of China.
Yuan NiuDepartment of Neurology, Second People's Hospital of Gansu Province, Lanzhou, People's Republic of China.
Xianhai ZengDepartment of Graduate and Scientific Research, Zunyi Medical University Zhuhai Campus, Zhuhai, People's Republic of China.
Jiangqi LiuDepartment of Graduate and Scientific Research, Zunyi Medical University Zhuhai Campus, Zhuhai, People's Republic of China.
Hailiang ZhaoDepartment of Graduate and Scientific Research, Zunyi Medical University Zhuhai Campus, Zhuhai, People's Republic of China.
Shuqi QiuDepartment of Graduate and Scientific Research, Zunyi Medical University Zhuhai Campus, Zhuhai, People's Republic of China.
Longgang Central Hospital · CNZunyi Medical University · CNNantong University · CNSecond People's Hospital of NanTong · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: To investigate the inhibitory effect of quercetin (QUE) on dendritic cells (DCs) through the toll-like receptor 4/interleukin-1 receptor-associated kinase 4/nuclear factor kappa-B (TLR4/IRAK4/NF-κB) signalling pathway. Material and methods: CCK-8 and apoptosis assays were performed to determine the optimal concentration and action time of QUE to inhibit DCs. Protein extracts from treated DCs were used for Western blotting experiments to determine the relative expression levels of TLR4, IRAK4, and NF-κB p65 proteins. Changes in the ratio of CD86 and CD11c positive cells on the DCs surface were detected using flow cytometry. The molecular docking technique was used to analyse the binding site and free energy of QUE and IRAK4. Results: CCK-8 and apoptosis assays suggested that QUE inhibited the activity and function of DCs in a time-dose-dependent manner. The results of Western blotting suggested that the relative expression levels of TLR4, IRAK4, and NF-κB p65 proteins were increased in the lipopolysaccharide (LPS) group compared with the normal control group, and the relative expression of the above proteins was decreased after treatment with QUE and IRAK4-IN-4. The results of flow cytometry suggested that LPS increased the expression of CD86 and CD11c on the surface of DCs, and QUE and IRAK4-IN-4 decreased the expression of CD86 and CD11c induced by LPS. Molecular docking results showed that the binding sites of QUE and IRAK4 were stable, with the minimum binding energies comparable to that of IRAK4-IN-4. Conclusions: Quercetin may inhibit the activity and function of DCs through the TLR4/IRAK4/NF-κB signalling pathway, and IRAK4 may be its target.

Indexed as

dendritic cellsquercetinTLR4/IRAK4/NF-κB signalling pathway

Identifiers

PMID38239865
PMCPMC10793624
OpenAlexW4390118383

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.